These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 22129953

  • 1. Evasion of the body snatchers.
    Marx RE.
    Implant Dent; 2009 Oct; 18(5):371-2. PubMed ID: 22129953
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Zoledronic acid and osteonecrosis of the jaw: incidence varies with use.
    Wynn RL.
    Gen Dent; 2011 Oct; 59(5):330-2. PubMed ID: 22313815
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Osteoporosis drugs linked to jawbone destruction.
    J Calif Dent Assoc; 2014 Jul; 42(7):435. PubMed ID: 25076619
    [No Abstract] [Full Text] [Related]

  • 7. Osteonecrosis of the jaw as a serious adverse effect of bisphosphonate therapy and its indistinct etiopathogenesis.
    Gavrić M, Antić S, Jelovac DB, Zarev AI, Petrović MB, Golubović M, Antunović M.
    Vojnosanit Pregl; 2014 Aug; 71(8):772-6. PubMed ID: 25181838
    [No Abstract] [Full Text] [Related]

  • 8. Bisphosphonate-related osteonecrosis of the jaws of dental origin.
    Pichardo SE, Richard van Merkesteyn JP.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Mar; 117(3):393. PubMed ID: 24440138
    [No Abstract] [Full Text] [Related]

  • 9. Commentary--Is the bone turnover of the jawbone and its possible over suppression by bisphosphonates of etiological importance for the pathogenesis of the bisphosphonate-related osteonecrosis?
    Carlson ER, Gerard DA.
    J Oral Maxillofac Surg; 2014 May; 72(5):911-3. PubMed ID: 24480759
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The case of the overlooked osteoclasts.
    Eisenberg S.
    ONS Connect; 2011 Nov; 26(11):21. PubMed ID: 22167997
    [No Abstract] [Full Text] [Related]

  • 12. [Osteonecrosis of the jaw associated with oral treatment with ibandronate].
    Ribas-Deix O, Sanz-Gallén P, Nogué S.
    An Sist Sanit Navar; 2011 Nov; 34(3):489-91. PubMed ID: 22233853
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacology: Discontinuation of bisphosphonates.
    Malden N, Loh S.
    Br Dent J; 2017 Jan 27; 222(2):67-8. PubMed ID: 28127004
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In reply.
    Allen MR, Chu TM, Ruggiero SL.
    J Oral Maxillofac Surg; 2013 Aug 27; 71(8):1307-8. PubMed ID: 23763902
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Implants and biphosphonates: 2012 guidelines for practitioners].
    Ruhin B.
    Rev Stomatol Chir Maxillofac Chir Orale; 2013 Feb 27; 114(1):e1-3. PubMed ID: 23711217
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.